Protalix BioTherapeutics (NYSE:PLX) Price Target Lowered to $12.00 at HC Wainwright

Protalix BioTherapeutics (NYSE:PLX) had its target price cut by HC Wainwright from $15.00 to $12.00 in a research note published on Friday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.03 EPS, Q1 2026 earnings at $0.04 EPS, Q2 2026 earnings at $0.05 EPS, Q3 2026 earnings at $0.05 EPS and Q4 2026 earnings at $0.06 EPS.

Protalix BioTherapeutics Trading Up 0.6%

Protalix BioTherapeutics stock traded up $0.01 during midday trading on Friday, reaching $1.75. 683,015 shares of the stock traded hands, compared to its average volume of 834,086. The firm has a market cap of $140.74 million, a PE ratio of -13.46 and a beta of -0.18. The company has a 50-day simple moving average of $2.18 and a two-hundred day simple moving average of $1.79. Protalix BioTherapeutics has a 12-month low of $1.32 and a 12-month high of $3.10.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets raised its position in shares of Protalix BioTherapeutics by 126.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,215 shares of the company’s stock worth $34,000 after acquiring an additional 8,498 shares in the last quarter. Orin Green Financial LLC boosted its holdings in shares of Protalix BioTherapeutics by 22.4% in the 2nd quarter. Orin Green Financial LLC now owns 61,200 shares of the company’s stock valued at $91,000 after buying an additional 11,200 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Protalix BioTherapeutics by 2.8% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 496,216 shares of the company’s stock valued at $734,000 after buying an additional 13,341 shares during the last quarter. NewEdge Advisors LLC acquired a new stake in Protalix BioTherapeutics during the 1st quarter worth $39,000. Finally, Virtu Financial LLC purchased a new stake in Protalix BioTherapeutics in the third quarter valued at $37,000. 16.53% of the stock is owned by institutional investors and hedge funds.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.